Liraglutide
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Novo Nordisk · Phase 2 · Completed · Enrollment 564
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Lira placebo/Lira 2.4 mg/Lira 3.0 mg | n/r | n/r | n/r | n/r |
| Lira 1.2 mg/Lira 3.0 mg | n/r | n/r | n/r | n/r |
| Lira 1.8 mg/Lira 3.0 mg | n/r | n/r | n/r | n/r |
| Lira 2.4 mg/Lira 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Orlistat | n/r | n/r | n/r | n/r |
Not shown
- Lira placebo/Lira 2.4 mg/Lira 3.0 mg: endpoint not reported
- Lira 1.2 mg/Lira 3.0 mg: endpoint not reported
- Lira 1.8 mg/Lira 3.0 mg: endpoint not reported
- Lira 2.4 mg/Lira 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Orlistat: endpoint not reported